Boardroom Alpha
10-K primary document
PLYX · Annual Report (Form 10-K) · Filed March 24, 2026

Polaryx Therapeutics Inc10-K exhibit

ea028171901ex10-13.htm

Exhibit 10.13

 

ADDENDUM #2 TO CONSULTANCY AGREEMENT

 

THIS ADDENDUM #2 TO CONSULTANCY AGREEMENT (“Addendum”) is made effective March 23, 2026 by and between: Polaryx Therapeutics, Inc., a Wyoming corporation (“Company”); and Mstone Partners Healthcare Limited, a Hong Kong corporation (“Mstone”). The Company and Mstone may herein be referred to individually as a “Party” and collectively as the “Parties”.

 

WHEREAS, the Parties entered into certain consultancy agreement dated 30 November 2021 (the “Agreement”) by which the Company has engaged Mstone as an independent consultant to the Company and Mstone has accepted the same engagement; and WHEREAS, each of the Parties wishes to make this Addendum to the Agreement for revision of certain provision thereof as set forth herein.

 

NOW, THEREFORE, the Parties agree as follows.

 

1. Article 3.1 of the Agreement is hereby replaced in its entirety with the following:

 

3.1 As full compensation for the Services and the rights granted to the Company in this Agreement, the Company shall pay Mstone a fixed amount of $90,000 beginning with the month of January 2026 based on the services rendered, payable in accordance with the payment schedule set forth in Schedule 1. Mstone acknowledges that Mstone shall be solely responsible for all federal, state, and local taxes, as set out in Section 4.2.

 

2. Except as set forth herein, all other terms of the Agreement will remain unchanged.

 

IN WITNESS WHEREOF, the undersigned parties have executed this Addendum effective as of the date first written above.

 

Polaryx Therapeutics, Inc.   Mstone Partners Healthcare Limited
     
By: /s/ G. Michael Landis   By: /s/ Alex Keun Mo Yang
Name: G. Michael Landis   Name: Alex Keun Mo Yang
Title: Chief Financial Officer, Director   Title: Director

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer